4D Molecular Therapeutics, Inc. (FDMT): Results of Operations and Financial Condition
4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Prese
How this was made
The 30-second read
Why it matters
Key trading inputs are updated Phase 3 topline windows (wet AMD 4FRONT-1 in Q2 2027, 4FRONT-2 in H2 2027), planned DME Phase 3 initiation in Q3 2026, and a Hercules credit facility (up to $200M, $20M initial draw) supporting funding into 2H 2028.
Market read
This is a catalyst-and-funding update for FDMT’s late-stage retinal programs, likely to affect positioning ahead of 2027 topline data and the Oct 21, 2026 Investor Day.
What to watch
The R&D expense increase and cash decline from $514.0M to $430.6M could offset optimism, and the credit facility terms (beyond initial draw) may matter for future dilution or covenants.
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
The company completed enrollment for 4FRONT-2, reported positive long-term PRISM data, and extended financial flexibility with a Hercules credit facility, but research and development expense and net loss increased as Phase 3 execution accelerated.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration and license revenueGAAP | $ 3,781 | – | – |
| Research and development expensesGAAP | $ 68,282 | – | – |
| General and administrative expensesGAAP | $ 12,524 | – | – |
| Total operating expensesGAAP | $ 80,806 | – | – |
| Loss from operationsGAAP | $ (77,025 ) | – | – |
| Other income, netGAAP | $ 4,089 | – | – |
| Net lossGAAP | $ (72,936 ) | – | – |
| Net loss per share, basic and dilutedGAAP | $ (1.04 ) | – | – |
| Weighted-average shares outstanding used in computing net loss per share, basic and dilutedGAAP | 70,272,018 | – | – |
| Cash, cash equivalents and marketable securitiesother | $ 430,629 | – | – |
| Total assetsother | 492,615 | – | – |
| Total liabilitiesother | 84,956 | – | – |
| Accumulated deficitother | (858,000 ) | – | – |
| Total stockholders’ equityother | 407,659 | – | – |
at least into the second half of 2028 outlook
- Note4FRONT-1 topline data expected in Q2 2027
- Note4FRONT-2 topline data expected in H2 2027
- NoteGlobal Phase 3 trial design and initiation expected in Q3 2026
- NoteSPECTRA clinical trial 2-year data expected in Q4 2026
- NoteAEROW Phase 1/2 clinical trial and program update expected in Q4 2026
- NoteCompany to host an Investor Day in New York City on October 21, 2026
What drove it
- The increase in collaboration and license revenue was primarily due to the clinical trial cost sharing and reimbursement amounts from Otsuka.
- The increase in research and development expenses was primarily driven by execution of 4D-150 Phase 3 clinical trials in wet AMD.
- 4FRONT-2 enrollment was completed in June 2026 with N>500 expected to be randomized.
- PRISM Phase 2b 2-year data reported 78% overall treatment burden reduction in the overall cohort and 87% overall treatment burden reduction in the recently diagnosed subgroup.
Concerns
- Net loss was $72.9 million for the second quarter of 2026, compared with net loss of $54.7 million for the second quarter of 2025.
- Research and development expenses were $68.3 million for the second quarter of 2026, compared with $48.0 million for the second quarter of 2025.
- All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority.
- The financial runway estimate depends on existing cash, cash equivalents and marketable securities and expected payments under the collaboration agreement with Otsuka.
What to watch
- 4D-150 DME Global Phase 3 trial design and initiation expected in Q3 2026.
- SPECTRA clinical trial 2-year data expected in Q4 2026.
- AEROW Phase 1/2 clinical trial and program update expected in Q4 2026.
- 4FRONT-1 topline data expected in Q2 2027.
- 4FRONT-2 topline data expected in H2 2027.
- Investor Day in New York City on October 21, 2026.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $430.6 million as of June 30, 2026, as compared to $514.0 million as of December 31, 2025.
- Secured credit facility for up to $200 million from Hercules Capital.
- Under the terms of the agreement, the Company drew an initial $20 million at closing.
- Total assets were 492,615 as of June 30, 2026, compared with 566,711 as of December 31, 2025.
- Total liabilities were 84,956 as of June 30, 2026, compared with 61,047 as of December 31, 2025.
- Total stockholders’ equity was 407,659 as of June 30, 2026, compared with 505,664 as of December 31, 2025.
Analysis
4DMT's quarter was defined by continued advancement of 4D-150 rather than commercial revenue generation. The company completed enrollment for 4FRONT-2 in wet AMD and retained its timeline for 4FRONT-1 topline data in Q2 2027 and 4FRONT-2 topline data in H2 2027. It also expects to initiate the DME Phase 3 trial in Q3 2026, creating a sequence of clinical milestones through 2027.
Reported collaboration and license revenue was $3.8 million for the second quarter of 2026, compared with an insignificant amount for the second quarter of 2025. Management attributed the increase primarily to Otsuka clinical-trial cost sharing and reimbursements. The filing does not report product revenue, operating segments, gross margin, or non-GAAP financial measures.
Investment in the pipeline increased materially. Research and development expenses were $68.3 million, compared with $48.0 million in the prior-year quarter, primarily due to execution of the 4D-150 wet AMD Phase 3 trials. Total operating expenses were $80.8 million and net loss was $72.9 million. The loss from operations was $77.0 million, while other income, net was $4.1 million.
Clinical data remain central to the program's value proposition. PRISM Phase 2b two-year data showed a 78% overall treatment burden reduction in the overall cohort and an 87% overall treatment burden reduction in the recently diagnosed subgroup. The company also reported no new cases of inflammation with 2 to more than 4 years of follow-up on all patients as of the data cutoff, alongside no observed 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions to date.
Liquidity and financing flexibility are key watchpoints as development spending rises. Cash, cash equivalents and marketable securities were $430.6 million as of June 30, 2026, compared with $514.0 million as of December 31, 2025. The company entered a Hercules facility for up to $200 million and drew an initial $20 million at closing. Management estimates that existing cash, cash equivalents and marketable securities and expected Otsuka payments will fund operating expenses and capital expenditure requirements at least into the second half of 2028.
Management, verbatim
The second quarter of 2026 reflected continued strong execution across 4DMT, including completion of enrollment for 4FRONT-2, presenting positive long-term PRISM data and strengthening our financial flexibility through securing a strategic credit facility with Hercules.
David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT
Not in the filing
stated, not guessed- Gross margin
- Non-GAAP revenue, expenses, operating income, net income, or earnings per share
- Prior-quarter comparisons for reported income-statement metrics
- Operating cash flow
- Free cash flow
- Capital expenditures
- Debt balance
- Share repurchases
- Dividends
- Financial revenue, gross margin, operating expense, or tax-rate guidance
- Prior-quarter outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
FDMT’s 8-K (Item 2.02) reports Q2 2026 financial results and operational milestones for its lead 4D-150 program in wet AMD and DME, plus funding updates.
Ticker impact
FDMT filed an 8-K with Q2 results plus updated clinical timelines, including 4FRONT-2 enrollment completion and topline data expected in H2 2027.
Moderate upside bias into the next clinical-data milestones, with volatility around Investor Day and any subsequent trial updates.
This is a primary disclosure (8-K with financials and operational milestones) that can re-rate risk for late-stage wet AMD and DME programs, and the $200M credit facility plus $430.6M cash supports funding visibility into 2H 2028.
Market effects
Reinforces investor appetite for durable anti-VEGF delivery platforms in retinal diseases, potentially improving sentiment for similar late-stage ophthalmology programs.
Limited direct regional impact; primarily US biotech sentiment.
Global Phase 3 enrollment completion and H2 2027 topline expectations may influence broader ophthalmology trial-risk perceptions.
Counterpoint
Clinical timelines remain forward-looking; without new efficacy readouts, the market may fade the news if burn rate and dilution risk re-emerge.
Key entities
- company4D Molecular Therapeutics, Inc.
Nasdaq-listed late-stage biotech advancing 4D-150 for wet AMD and DME; reported Q2 2026 results and milestone updates in an 8-K.
- credit_facility_counterpartyHercules Capital, Inc.
Provided a strategic credit facility to FDMT for up to $200 million, with an initial $20 million draw at closing.
- collaboration_partnerOtsuka
Clinical trial cost sharing and reimbursement contributed $3.8 million in Q2 2026 collaboration and license revenue.
